Sutro Biopharma (STRO) Net Equity Issued and Repurchased (2019 - 2024)

Sutro Biopharma (STRO) reported Net Equity Issued and Repurchased of -$50.0 million for Q2 2024, down 134.92% sequentially from $143.2 million in Q4 2020.

Sutro Biopharma (STRO) Net Equity Issued and Repurchased (2019 - 2024) Analysis & Trends

Sutro Biopharma (STRO) has 3 years of Net Equity Issued and Repurchased data on file, last reported at -$50.0 million in Q2 2024.

  • For the quarter ending Q2 2024, Net Equity Issued and Repurchased changed N/A year-over-year to -$50.0 million; the trailing twelve-month figure through Sep 2025 stood at -$50.0 million (down 145.47% YoY), and the FY2024 full-year result was $25.0 million, changed N/A from the prior year.
  • Net Equity Issued and Repurchased retreated to -$50.0 million in Q2 2024, from $143.2 million in the prior quarter.
  • In the past five years, Net Equity Issued and Repurchased ranged from a high of $143.2 million in Q4 2020 to a low of -$50.0 million in Q2 2024.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Equity Issued and Repurchased (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn -
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 163.10 Mn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - 141.90 Mn
10 Sutro Biopharma 202.59 Mn 61.16 Mn - -

Historic Data

Download Data
DateValue
Jun 30, 2024 -50.00 Mn
Jun 30, 2024 -50.00 Mn
Dec 31, 2020 143.17 Mn
Dec 31, 2020 143.17 Mn
Sep 30, 2020 16.80 Mn
Sep 30, 2020 16.80 Mn
Dec 31, 2019 -327,000.00
Dec 31, 2019 -327,000.00